Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Musculoskeletal Care ; 2(3): 187-93, 2004.
Article in English | MEDLINE | ID: mdl-17041982
3.
Musculoskeletal Care ; 1(1): 44-57, 2003 Mar.
Article in English | MEDLINE | ID: mdl-20217663

ABSTRACT

This article provides an overview of the immune system with a specific focus on the role of biologic therapies in treating the consequences of an altered immune response as seen in rheumatoid arthritis (RA). Cytokines are powerful chemical messengers that have a significant role to play in activating an inflammatory response. Two dominant cytokines have been identified as crucial in the inflammatory process that can be seen in RA-tumour necrosis factor alpha (TNFalpha) and interleukin-1. The term 'biologic' is used to describe biologically engineered therapies that are specifically designed to prevent pro-inflammatory cytokines inducing an inflammatory response. Research trials and now clinical practice have clearly demonstrated a significant benefit to patients receiving biologic therapies. The responsibility of the practitioner is to ensure a sound knowledge of biologic therapies, to understand the essential aspects of care and to recognize the importance of guidance documents available to support management and, ultimately, the long-term provision of safe and effective administration of these therapies.


Subject(s)
Antirheumatic Agents/immunology , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/therapy , Biological Therapy , Clinical Trials as Topic , Humans , Immune System/immunology , Immunologic Factors/immunology , Immunologic Factors/therapeutic use , Joint Diseases/immunology , Joint Diseases/therapy , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...